Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)

Phase 1 Completed 25 enrolled Bayer Novartis · collab

RandomizedParallel-groupSingle-blindTreatment

Summary

Objectives of the study are to investigate the safety, tolerability and levels of ciprofloxacin in the lung after single and multiple inhalative administration to patients with mild to moderate COPD (stage I-II according to GOLD Criteria).

Timeline

Start: 2009-04
Primary completion: 2009-09
Completion: 2009-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ciprofloxacin	Small molecule	32.5 mg	Inhaled
Subject	Ciprofloxacin	Small molecule	48.75 mg	Inhaled

Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)

Summary

Timeline

Drugs

Indications